

Engagement Report for Clinical Commissioning Policies

Unique Reference Number	1822 ID016
Policy Title	Doravirine for treating HIV infection
Clinical Reference Group	HIV Clinical Reference Group
Which stakeholders were contacted to be involved in policy development?	<p>A policy working group was established in line with NHS England's standard methods.</p> <p>The draft policy proposition was sent to the following groups for comment:</p> <ul style="list-style-type: none"> • HIV Clinical Reference Group (CRG); and • Registered stakeholders for the HIV CRG
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	All of the relevant Royal Colleges and professional societies were invited to take part in stakeholder testing.
Which stakeholders have actually been involved?	5 responses were received from stakeholders, including an individual clinician, BHIVA, RCP, a healthcare professional and a pharmaceutical company.
Explain reason if there is any difference from previous question	Not all organisations commented on the documents.
Identify any particular stakeholder organisations that may be key to the policy development	None, the main patient and carer representative organisations were involved throughout the development of the draft policy proposition

<p>that you have approached that have yet to be engaged. Indicate why?</p>	
<p>How have stakeholders been involved? What engagement methods have been used?</p>	<p>Policy working group meeting and subsequent contact for policy development The draft policy proposition was distributed to stakeholders via email for a period of two weeks of stakeholder testing, in preparation for public consultation. Stakeholders were asked to submit their responses via email, using a standard response and in line with NHS England's standard processes for developing clinical commissioning policies.</p>
<p>What has happened or changed as a result of their input?</p>	<p>Comments were submitted by 5 stakeholders and these have been reviewed by the policy working group. An amendment was made to the clinical evidence review following consideration by the PWG. The following text was added to section 2.38 in the Evidence gaps and limitations section: 'None of the studies directly compare doravirine to an integrase inhibitor.'</p>
<p>How are stakeholders being kept informed of progress with policy development as a result of their input?</p>	<p>All stakeholders (including CRG members and registered stakeholders) will be notified when the draft policy proposition goes out to public consultation and will be kept informed of the policy's progress through NHS England's consultation portal website It is proposed that highly specialised products will go for period of public consultation for four weeks.</p>
<p>What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?</p>	<p>It is proposed that highly specialised products will go for period of public consultation for four weeks.</p>